Programmed death ligand 1 (PD-L1, also known as CD274) expression has been proposed as one of the pan-cancer biomarkers for immunotherapy including GC, breast cancer, lung cancer, etc. [37, 38]. This evidence concerns the gene CD274 and lung cancer.